Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT04483284 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

Start date: June 24, 2020
Phase: Phase 2
Study type: Interventional

It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until disease progression or intolerable toxicity or patients withdrawal of consent,and the target sample size is 60 individuals.

NCT ID: NCT04258566 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies

Start date: January 27, 2022
Phase: Phase 1
Study type: Interventional

Background: Liver cancer is the sixth most common cancer worldwide. Diagnosing liver cancer usually requires a liver sample. Getting the best sample helps determine whether cancer is present and what kind of cancer it is. But sampling can be difficult. This study will look at combining two devices to provide better liver samples. Objective: To see if combining fusion imaging and optical imaging can better sample areas of concern in the liver and determine the presence of disease. Eligibility: People ages 18 and older who need a liver biopsy as part of diagnosis or treatment. Design: Participants will be screened with: Review of imaging Medical history Physical exam Blood test results Participants will have a dye injected into a vein 24 hours before their biopsy. They will be monitored for 30 minutes for any side effects. For the biopsy, participants skin will be numbed. They may have stickers placed on their belly to help guide the needle. They will have a CT scan to plan the needle s pathway. For the scan, they will lie in a machine that takes pictures of the body. A small camera will be placed near the needle to take pictures of the liver. A medical GPS tracking system will be used. This will guide the needle into the area of the participant s liver where the biopsy will be taken. After the biopsy, participants will recover in the hospital for 4 6 hours. After the procedure, researchers will take the participants biopsy tissue and look at it to try to compare new ways to picture the sample.

NCT ID: NCT04160897 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis

Start date: October 22, 2019
Phase:
Study type: Observational

The current first-line treatment for HBV is long-term oral antiviral drugs to inhibit HBV DNA replication. First-line antiviral drugs recommended by the Chinese 2015 Hepatitis B Guidelines include ETV and TDF. This study is based on a real-world clinical cohort to retrospectively analyze the effects of ETV and TDF on the long-term (5-year) incidence of HCC in Chinese patients with chronic hepatitis B with compensated cirrhosis. The results will guide the revision of the Chinese HBV guidelines.

NCT ID: NCT03739164 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)

TAMLAPS
Start date: July 18, 2018
Phase:
Study type: Observational [Patient Registry]

This is a study following the outcomes and survival of patients undergoing the TAMLAPS hepatectomy at Florida Hospital Tampa by Dr. Iswanto Sucandy

NCT ID: NCT03516448 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Expanding Phase III Study of Tyroserleutide for Injection

Start date: March 24, 2016
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions 21 days after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment groups:6mg/d Tyroserleutide (injection), or placebo

NCT ID: NCT03069508 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Clemizole HCl for Subjects With Hepatocellular Carcinoma

Start date: February 13, 2017
Phase: Phase 2
Study type: Interventional

This study is a phase IIa open label pilot study of up to six months treatment with clemizole hydrochloride (200 mg vs. 300 mg vs. 400 vs. 500 mg mg) given orally TID to subjects with hepatocellular carcinoma that are either awaiting transplantation or have an unresectable lesion.

NCT ID: NCT02830737 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

No-touch RFA Versus Traditional RFA for Small Hepatocellular Carcinoma

Start date: January 2016
Phase: N/A
Study type: Interventional

Traditional RFA treatment has been a curable therapy for small hepatocellular carcinoma (diameter≤3cm). This technique ablates the tumor via radio frequency by inserting an electrode needle directly into the tumor. This clearly violates no-touch technique based on the principle of surgical oncology. Thus the 1-year recurrence rate of the cancer is up to 30% after the treatment, and the 3-year tumor-free survival rate is only 20% - 40%. No-touch RFA treatment avoids the direct contact with the tumor that can cause the spread of cancer cells in the liver, or the Antrim spread, Therefore it has been suggested that no-touch RFA treatment reduce the recurrence rate after operation in comparison with the traditional RFA treatment. This research project aims at using the prospective randomized comparative method to compare the short-term and the long-term curative effects between no-touch RFA and traditional RFA treatments for small hepatic carcinoma.

NCT ID: NCT02757846 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Radiomics of Hepatocellular Carcinoma

Start date: April 2017
Phase: N/A
Study type: Observational

We propose a radiomics approach to identify prognostic biomarkers of HCC and provide patients with some reasonable advice for their therapies.

NCT ID: NCT01715402 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Optimization of Health Expenditure in Liver Surgery

Start date: September 2012
Phase: N/A
Study type: Observational

The aim of this study is to reduce the length of stay after liver surgery by taking account of objective quantitative clinical variables, subjective qualitative clinical variables and non clinical variables.

NCT ID: NCT01489566 Enrolling by invitation - Clinical trials for Hepatocellular,Carcinoma

Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients

Start date: July 2011
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions one month after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment groups:6mg/d Tyroserleutide (injection), or placebo. The objective is to evaluate the effect of Injectable Tyroserleutide on the recurrence-free survival,overall survival,quality of life,and the safety and tolerability of subjects after the resection of hepatocellular carcinoma